Clinical Trial Update: Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib, vorinostat, and dexamethasone for relapsed/refractory acute lymphoblastic leukemia has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Vorinostat (vorinostat)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2015-05-15